<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319641</url>
  </required_header>
  <id_info>
    <org_study_id>104902</org_study_id>
    <nct_id>NCT03319641</nct_id>
  </id_info>
  <brief_title>PSMA-PET Imaging for Advanced ACC/SDC</brief_title>
  <official_title>68Ga-PSMA-PET/CT Imaging for Locally Advanced, Recurrent and Metastatic Adenoid Cystic Carcinoma or Salivary Duct Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adenoid Cystic Carcinoma Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnostic study which evaluates the level of PSMA expression in patients with locally
      advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging
      in order to establish whether these patients are eligible for 177Lu-PSMA therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: PSMA is a transmembrane protein, which is expressed on prostate cancers cells, ACC
      and other malignancies. In prostate cancer, distant metastases can be visualized sensitively
      and non-invasively with 68Ga-PSMA-PET/CT scans and if the uptake of 68Ga is high enough,
      patients can be treated with the β-emitting radionuclide 177Lu-PSMA. In the current study, we
      will evaluate the uptake of 68Ga-PSMA by performing 68Ga-PSMA-PET/CT scans in advanced ACC
      and SDC patients. If the uptake is high enough, this will form the rationale for a
      therapeutic study with 177Lu-PSMA in ACC and SDC.

      Objective: The primary objective is to evaluate the uptake of 68Ga-PSMA in locally advanced,
      recurrent and metastatic ACC/SDC by performing 68Ga-PSMA-PET/CT scans. The secondary
      objectives are to calculate the SUV tumor-to-background ratio and tumor-to-'healthy salivary
      gland tissue' ratio. To correlate the SUV to the degree of immunohistochemical PSMA
      expression of the primary tumor on archival tissue, and to establish whether new metastatic
      lesions are found by 68GA-PSMA-PET/CT imaging.

      Study design: Diagnostic study which evaluates the level of PSMA expression in ACC/SDC
      patients with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are
      eligible for 177Lu-PSMA therapy.

      Study population: Patients with locally advanced, recurrent or metastatic ACC/SDC of ≥18
      years old.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Anticipated">February 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>diagnostic study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>uptake of 68Ga-PSMA in ACC and SDC</measure>
    <time_frame>0 days</time_frame>
    <description>To evaluate the uptake of 68Ga-PSMA in locally advanced, recurrent and metastatic ACC/SDC by performing 68Ga-PSMA-PET/CT scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SUV of 68Ga-PSMA in ACC/SDC tumors</measure>
    <time_frame>0 days</time_frame>
    <description>SUV of 68Ga-PSMA in ACC/SDC tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUV of 68Ga-PSMA in the background</measure>
    <time_frame>0 days</time_frame>
    <description>in order to calculate the SUV tumor to background ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation of SUV and IHC PSMA-staining</measure>
    <time_frame>0 days</time_frame>
    <description>Correlate the tumor uptake (SUV) to the degree of immunohistochemical PSMA expression of the primary tumor on archival tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new metastases</measure>
    <time_frame>0 days</time_frame>
    <description>To establish whether new metastatic lesions are found by 68GA-PSMA-PET/CT imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Salivary Gland Cancer</condition>
  <condition>Adenoid Cystic Carcinoma</condition>
  <condition>Salivary Duct Carcinoma</condition>
  <arm_group>
    <arm_group_label>PSMA-PET/CT scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PSMA-PET/CT imaging in advanced ACC/SDC</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PSMA-PET/CT scan</intervention_name>
    <description>perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC</description>
    <arm_group_label>PSMA-PET/CT scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  locally advanced, recurrent or metastatic ACC/SDC

          -  Age ≥ 18 years old

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Contra-indication for PET imaging

          -  Pregnancy

          -  Breast feeding

          -  Severe claustrophobia

          -  Impaired renal function: MDRD &lt;30 ml/min/1,73 m2

          -  Impaired liver function: AST and ALT ≥ 2.5 x ULN (≥5 x ULN for patients with liver
             metastases)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla ML van Herpen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla ML van Herpen, MD, PhD</last_name>
    <phone>024 3667251</phone>
    <email>Carla.vanherpen@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wim van Boxtel, MD</last_name>
    <phone>+31625034690</phone>
    <email>wim.vanboxtel@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla ML van Herpen, MD, PhD</last_name>
      <phone>024 3667251</phone>
      <email>Carla.vanHerpen@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Wim van Boxtel, MD</last_name>
      <phone>+31625034690</phone>
      <email>Wim.vanBoxtel@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Carla van Herpen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>68Ga-PSMA</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Immunohistochemistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

